Is survodutide approved?

No — as of April 2026 survodutide is in late-phase clinical trials and not commercially available outside trial settings.

Survodutide Calculator

Also known as: BI 456906

GLP-1

Default: 10mg / 2mL / 1.2mgAdjust inputs to match your vial

About

What is Survodutide?

Survodutide is a dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 obesity trials reported up to 19% mean weight loss at the highest dose. As of April 2026 it remains investigational.

Common vial sizes

6 mg	lyophilized powder
10 mg	lyophilized powder

Reference dose ranges

0.6 mg	≈ 12 U-100 units (at 10mg / 2mL)
1.2 mg	≈ 24 U-100 units (at 10mg / 2mL)
2.4 mg	≈ 48 U-100 units (at 10mg / 2mL)
3.6 mg	≈ 72 U-100 units (at 10mg / 2mL)
4.8 mg	≈ 96 U-100 units (at 10mg / 2mL)

Reconstitution

How it's typically prepared

Reconstitute with BAC water; refrigerate.

FAQ

Frequently asked questions

Is survodutide approved?: No — as of April 2026 survodutide is in late-phase clinical trials and not commercially available outside trial settings.

Sources

References

PubMed search: survodutide

Other GLP-1 peptides

Notice

PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.